Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
The New England journal of medicine November 3, 2022 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 1,095 citations
Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...